PMD69 Treatment of Urinary Tract infections is Common amongst Swedish Patients in Need of Chronic Catheterisation  by Bruce, S. et al.
RESULTS: A substantial share of the variance (around 20%) was related to the
hospital level. Preliminary results suggest that supplementary fees had a border-
line significant positive impact on DES use. Further hospital characteristics also
had a significant impact on the use of DES (p0.05), as well as area characteristics.
CONCLUSIONS: Although there seems to be a small influence of supplementary
fees on the use of DES, further hospitals’ and area characteristics might be of higher
importance than reimbursement incentives. Attributing the diffusion of technolo-
gies to financial incentives only would fall too short.
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OBJECTIVES: Systematic analysis of the available studies of the clinical effective-
ness and safety of negative pressure therapy, as compared with traditional courses
of treatment, in complex foot wounds in diabetic patients. METHODS: A biblio-
graphical search was performed in the following databases: Embase.com, Medline
and Cochrane Library, covering from 2000 until the present. The following descrip-
tors and key words were used: diabetic foot, negative-pressure wound, vacuum-
assisted closure and diabetic ulcers. The Jaddad criteria were used to determine the
quality of the clinical trials. The studies selected were randomized clinical trials
that featured patients older tan 18 years, with complex ulcers, postoperative
wounds, or wounds resulting from the amputation of the foot, with a control group
comparing negative pressure therapy with conventional therapies (saline solution,
alginates or hydrophilic substances. The treatments were applied every 48 hours. A
total of 12 studies, of which only 7 were pertinent, were selected. Two independent
reviewers extracted the information and determined the methodological quality of
the selected studies. RESULTS: Of the 7 studies selected (539 patients), 5 involved
patients with postoperative wounds and 2 used the same group of patients. One of
the two studies involving ulcers of the foot was limited by its simple size (N10).
The methodological quality of the studies is moderate-low. CONCLUSIONS: The
evidence supports the effectiveness and security of negative pressure wound ther-
apy in complex foot ulcers in diabetic patients. Given that it is unlikely that further
research will change this positive appraisal (despite the moderate-low quality of
the studies analyzed, its cost profile and the absence of adverse effects) it is possi-
ble to make a strong recommendation in favor of the therapy.
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OBJECTIVES: Based on clinical trial evidence, remote follow-up (FU) has been rec-
ommended for replacing in office visits routinely scheduled to monitor device
functionality and health status of patients with CIED. No data exist on the actual
demand for such visits. To estimate the total number of calendar based in-office FU
visits in Germany and the UK (UK) by 2015. METHODS: Official national sales data
for implantable pacemakers (PM), cardioverter defibrillators (ICD) and cardiac re-
synchronisation therapy (CRT) devices were combined with published replace-
ment rates and estimates for patient mortality and device longevity. Following
HRS/EHRA guidelines on FU frequency, demand for FU consultations until 2015 was
modelled. RESULTS: For 2010, the model estimates about 677’800 prevalent pa-
tients with a CIED in Germany and 225,000 in the UK. The growth in CIED patients
recently seen in the UK is expected to slow down but to continue to be higher than
in Germany (8.3% per annum until 2015 versus 4.8%). Assuming two annual visits
for PM patients and four visits for ICD and CRT patients, the total number of routine
FU visits is estimated to increase from 1.66 mio in Germany (2010) to 2.23 mio
(2015). For the UK, service numbers will increase from 538,000 (2010) to 836,000
(2015). These estimates do not include unscheduled FU visits. CONCLUSIONS: Reg-
ular FU services for CIEDs are mandatory to ensure device functionality and mon-
itor disease status. Increasing patient volumes will push demand for these ser-
vices, placing a potentially unmanageable burden on cardiology service providers,
payers and patients, unless infrastructure investments occur. High demand for
services and low actionability of routine visits may result in inappropriate guide-
line adherence with potentially negative impact on patient safety and device lon-
gevity. Clinics need to become aware of this situation and adopt strategies for
handling the expected workload in the future.
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OBJECTIVES: To assess the cost-effectiveness of transcatheter aortic valve implan-
tation (TAVI) versus medical management (MM) for severe aortic stenosis (AS) in
elderly patients with excessive surgical risk. METHODS: A Markov model was de-
veloped of survival, quality-adjusted life-years (QALYs) and medical costs, in el-
derly patients in the UK with severe AS and excessive risk for conventional aortic
valve replacement (cAVR). Incremental cost-effectiveness ratios (ICERs) were esti-
mated as cost per QALY-gained, from the National Health Service (NHS) perspec-
tive, over 3 years. Clinical and utility outcomes over the first year were derived from
published results of a head-to-head randomized controlled trial comparing [trans-
femoral] TAVI and MM. Base-case analyses assumed no additional procedure-re-
lated adverse events after the first year—not including re-hospitalizations due to
cardiovascular events—and constant treatment-specific mortality after the first
month. Costs of procedures, adverse events, re-hospitalizations and long-term
health care utilization were estimated using NHS tariff and reference cost sched-
ules, National Institute of Health and Clinical Excellence reports, peer-reviewed
literature and clinical experts. Outcomes and costs (2010£) were discounted at 3.5% per
annum. RESULTS: Under conservative assumptions, treatment with transfemoral
TAVI is estimated to result in better survival (35% vs. 13% at three years) and more
QALYs (1.17 vs. 0.76) than MM. TAVI is also associated with higher costs of initial
treatment and procedure-related adverse events, partially offset by lower costs of
re-hospitalizations (net costs of £34,500 vs. £23,700). The base-case ICER of £26,100
is sensitive to variation in assumptions about long-term mortality for MM and
long-term cardiovascular events for TAVI but remains below £30,000; the model is
also sensitive to assumptions on long-term care use. CONCLUSIONS: In elderly
patients who are contraindicated for cAVR, TAVI is estimated to result in better
survival and fewer re-hospitalizations over a three-year period compared with MM,
and can be considered cost-effective at 3 years with a base-case ICER of £26,000.
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OBJECTIVES: The objectives of this study were to: 1) evaluate, from a global per-
spective, the decision-making processes, roles of individuals involved, and physi-
cians’ and administrators’ beliefs about future decision making for the adoption of
cardiovascular devices and medical technologies; and 2) determine which clinical
and health economic factors decision makers consider the most influential and
what types of data they use when making decisions. METHODS: We surveyed
cardiovascular physicians and hospital administrators in the US, UK, Australia,
France, Germany, and Japan using a web-based questionnaire. Respondents were
asked about their involvement in and opinions on the decision-making process in
their institutions, and the role that clinical and economic data play in influencing
decisions. Chi-squared tests were used to test for statistical differences between
physicians and hospital administrators (all countries combined) and across
countries. RESULTS: The questionnaire was completed by 151 physicians and 154
administrators across the six countries with roughly 25 physicians and 25 hospital
administrators responding from each. Physicians, followed by hospital commit-
tees, were most frequently responsible for making decisions, but respondents be-
lieved influence would shift towards committees in the future. Physicians (78%)
and administrators (81%) believed costs would more heavily influence decisions in
the next 5 years. Approximately half of hospital administrators consulted eco-
nomic data often when making device adoption decisions. Use varied somewhat by
country with most frequent use by both physicians and hospital administrators in
the U.S., U.K., and Australia. CONCLUSIONS: Physicians’ and hospital administra-
tors’ roles in decision making for cardiovascular devices appear to be changing in
many countries, with committees and administrators assuming more important
roles. While clinical data is most influential to the decision process, the impact of
health economic data seems to be growing.
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OBJECTIVES: To collect real-life data from a Swedish setting on treatment patterns
and frequency of urinary tract infection (UTI), amongst patients in presumed need
of chronic, intermittent catheterisation.METHODS:We used the CEBRxA database,
which combines data from a public claims database for the South-West region of
Sweden, comprising around 1.5 million individuals, with national Swedish regis-
ters on drug utilisation and mortality. We identified two sets of patients; Population
I: spinal injury, in addition to neurogenic bladder, and Population II: self-catheteri-
sation training (GB005). A list of antibiotics, known for their frequent use in treating
UTIs was used to evaluate treatment patterns. In addition, a prophylactic treat-
ment for UTI was evaluated (J01AXX05). An antibiotic regime was defined through
considering all dispatches that occurred within 14 days from each other, simulta-
neously (data available from 2005-07-01 until 2009-12-31). RESULTS: We identified
295 and 989 patients for Population I and II, respectively. Both populations con-
sisted primarily of males, while Population I was on average much younger (44 vs.
65 years). For Population I, we observed an average frequency of 2.5 UTI-related anti-
biotic regimes per year. For Population II, an average rate of 1.9 UTIs per year was
observed, while females showed an elevated rate of 2.5. Interestingly, prophylactic use
of antibiotics was widespread in Population I, with usage in 25% of patients, while for
Population II, only 3% of patients had dispatched J01AXX05. An evaluation of the
prescribed dose for Population I prophylaxis users, pointed to an almost continuous
use, at an average 235 DDD per patient and year. CONCLUSIONS: Through studying
UTI-related antibiotic treatment patterns we demonstrated a high disease burden
for UTIs in two, primarily male, populations, in presumed catheterisation need.
The frequent use of prophylactic treatment in the spinal injury population pointed
to an even larger disease burden for these patients.
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